CRSP stock icon

CRISPR Therapeutics
CRSP

$65.26
2.11%
 

About: Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Employees: 407

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 16 analysts
0
News positive %
of 24 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

17% more call options, than puts

Call options by funds: $196M | Put options by funds: $167M

17% more capital invested

Capital invested by funds: $3.48B [Q4 2023] → $4.05B (+$576M) [Q1 2024]

13% more repeat investments, than reductions

Existing positions increased: 153 | Existing positions reduced: 135

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 4 (+0) [Q1 2024]

0.47% less ownership

Funds ownership: 69.91% [Q4 2023] → 69.45% (-0.47%) [Q1 2024]

1% less funds holding

Funds holding: 466 [Q4 2023] → 463 (-3) [Q1 2024]

4% less first-time investments, than exits

New positions opened: 67 | Existing positions closed: 70

Research analyst outlook

16 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$48
26%
downside
Avg. target
$80
23%
upside
High target
$112
72%
upside

16 analyst ratings

positive
56%
neutral
38%
negative
6%
Citigroup
Yigal Nochomovitz
29%upside
$84
Buy
Maintained
23 May 2024
Oppenheimer
Jay Olson
46%upside
$95
Outperform
Maintained
10 May 2024
JMP Securities
Silvan Tuerkcan
32%upside
$86
Market Outperform
Reiterated
9 May 2024
Wells Fargo
Yanan Zhu
0%downside
$65
Equal-Weight
Maintained
9 May 2024
Barclays
Gena Wang
3%upside
$67
Equal-Weight
Maintained
9 May 2024

Financial journalist opinion

Based on 24 articles about CRSP published over the past 30 days